Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases

Eur J Gastroenterol Hepatol. 2000 Mar;12(3):365-8. doi: 10.1097/00042737-200012030-00017.


This report describes two patients who developed jaundice within two weeks of receiving an amoxycillin-clavulanate potassium combination. Causes of jaundice, other than drug administration, were excluded. The patients' jaundice and clinical symptoms did not respond to stopping the drug. Ursodeoxycholic acid (750 mg/day) led to a prompt and sustained improvement in their hyperbilirubinaemia and symptoms such as pruritus and fatigue. These cases suggest that ursodeoxycholic acid may be an effective treatment for drug-associated cholestasis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amoxicillin-Potassium Clavulanate Combination / adverse effects*
  • Biopsy
  • Cholagogues and Choleretics / therapeutic use*
  • Cholestasis, Intrahepatic / chemically induced
  • Cholestasis, Intrahepatic / drug therapy*
  • Cholestasis, Intrahepatic / pathology
  • Drug Therapy, Combination / adverse effects*
  • Humans
  • Liver / pathology
  • Male
  • Prognosis
  • Ursodeoxycholic Acid / therapeutic use*


  • Cholagogues and Choleretics
  • Ursodeoxycholic Acid
  • Amoxicillin-Potassium Clavulanate Combination